Historical Valuation
Surgery Partners Inc (SGRY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.56 is considered Undervalued compared with the five-year average of -328.94. The fair price of Surgery Partners Inc (SGRY) is between 21.10 to 38.54 according to relative valuation methord. Compared to the current price of 15.71 USD , Surgery Partners Inc is Undervalued By 25.53%.
Relative Value
Fair Zone
21.10-38.54
Current Price：15.71
25.53%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Surgery Partners Inc (SGRY) has a current Price-to-Book (P/B) ratio of 1.13. Compared to its 3-year average P/B ratio of 1.83 , the current P/B ratio is approximately -38.35% higher. Relative to its 5-year average P/B ratio of 3.42, the current P/B ratio is about -66.94% higher. Surgery Partners Inc (SGRY) has a Forward Free Cash Flow (FCF) yield of approximately 9.90%. Compared to its 3-year average FCF yield of 4.80%, the current FCF yield is approximately 106.12% lower. Relative to its 5-year average FCF yield of 4.16% , the current FCF yield is about 137.78% lower.
P/B
Median3y
1.83
Median5y
3.42
FCF Yield
Median3y
4.80
Median5y
4.16
Competitors Valuation Multiple
AI Analysis for SGRY
The average P/S ratio for SGRY competitors is 0.33, providing a benchmark for relative valuation. Surgery Partners Inc Corp (SGRY.O) exhibits a P/S ratio of 0.56, which is 72.17% above the industry average. Given its robust revenue growth of 6.63%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for SGRY
1Y
3Y
5Y
Market capitalization of SGRY increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SGRY in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is SGRY currently overvalued or undervalued?
Surgery Partners Inc (SGRY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.56 is considered Undervalued compared with the five-year average of -328.94. The fair price of Surgery Partners Inc (SGRY) is between 21.10 to 38.54 according to relative valuation methord. Compared to the current price of 15.71 USD , Surgery Partners Inc is Undervalued By 25.53% .
What is Surgery Partners Inc (SGRY) fair value?
SGRY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Surgery Partners Inc (SGRY) is between 21.10 to 38.54 according to relative valuation methord.
How does SGRY's valuation metrics compare to the industry average?
The average P/S ratio for SGRY's competitors is 0.33, providing a benchmark for relative valuation. Surgery Partners Inc Corp (SGRY) exhibits a P/S ratio of 0.56, which is 72.17% above the industry average. Given its robust revenue growth of 6.63%, this premium appears unsustainable.
What is the current P/B ratio for Surgery Partners Inc (SGRY) as of Jan 09 2026?
As of Jan 09 2026, Surgery Partners Inc (SGRY) has a P/B ratio of 1.13. This indicates that the market values SGRY at 1.13 times its book value.
What is the current FCF Yield for Surgery Partners Inc (SGRY) as of Jan 09 2026?
As of Jan 09 2026, Surgery Partners Inc (SGRY) has a FCF Yield of 9.90%. This means that for every dollar of Surgery Partners Inc’s market capitalization, the company generates 9.90 cents in free cash flow.
What is the current Forward P/E ratio for Surgery Partners Inc (SGRY) as of Jan 09 2026?
As of Jan 09 2026, Surgery Partners Inc (SGRY) has a Forward P/E ratio of 24.62. This means the market is willing to pay $24.62 for every dollar of Surgery Partners Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Surgery Partners Inc (SGRY) as of Jan 09 2026?
As of Jan 09 2026, Surgery Partners Inc (SGRY) has a Forward P/S ratio of 0.56. This means the market is valuing SGRY at $0.56 for every dollar of expected revenue over the next 12 months.